

UBS Investment Research Indian IT Services

Global Equity Research

India

Software

Sector Comment

All eyes on Infosys guidance

■ Not unreasonable to expect revenue guidance of 19-21% from Infosys

We expect strong revenue guidance from Infosys Technologies (Infosyss) for FY12, based on our view that demand recovery is likely to be more broad-based in 2011. The strong revenue numbers reported by Accenture in its recent earnings announcement also point to a strong recovery in discretionary spending in 2011, in our view. We expect dollar revenue guidance of 19-21% YoY from Infosys on 15 April 2011.

■ Margin focus, wage outlook to be key points to watch out for

With revenue recovery stabilising, and most Indian vendors reporting significant operating margin declines in FY11, we expect investor focus to shift to the margin outlook in FY12. Wage hikes are the primary drag on margins and we expect announcements from Infosys and Tata Consultancy Services (TCS) to set the base for the rest of the industry.

■ Q4 FY11 likely to be in line, no major surprise likely

We expect large cap vendors to report 5-6% revenue growth, with most vendors reporting margin increases during the quarter. We expect net profit to grow faster than revenue for most large vendors. We expect mid-sized vendors to continue to report relatively weaker numbers.

■ UBS view: Infosys remains top pick, with strong guidance expectations

We believe that strong revenue guidance from Infosys will overshadow a likely conservative margin outlook and act as a strong catalyst for further share price upside potential. We maintain our Buy rating on Infosys, which is our top pick in the Indian IT services sector. We maintain our Neutral rating on TCS and our Sell ratings on Wipro and HCL Technologies. We remain more cautious on mid-cap stocks.

Table 1: Q4 FY11 estimates

Q4 FY11E	Revenue (Rs m)	% QoQ	EBITDA margin	Inc/(Dec) - bps	PAT (Rs m)	% QoQ
Infosys	74,970	5.5%	33.6%	31	19,040	7.0%
TCS	102,495	6.1%	29.7%	(49)	24,155	2.5%
Wipro	82,311	5.3%	21.5%	59	14,203	8.4%
HCL Tech	40,506	4.9%	17.1%	77	4,353	9.6%
Patni	8,801	7.3%	16.6%	66	1,366	-22.6%
MphasiS	12,612	2.2%	19.4%	(146)	2,010	-11.3%
Tech Mahindra	12,569	3.8%	18.8%	(184)	1,825	-29.0%

Note: Year-end June 2011 for HCLT; December 2011 for Patni; October 2011 for MphasiS.

Source: Company data, UBS estimates

4 April 2011

www.ubs.com/investmentresearch

Diviya Nagarajan Analyst diviya.nagarajan@ubs.com +91-22-6155 6072

Table 2: Valuation comparison

		Mkt. Cap		Potential upside			EPS CAGR	
	Price (Rs)	(US\$ bn)	Rating	(%)	PE (x)	EV/EBITDA (x)	FY11-13E (%)	
TCS	1,180	51.9	Neutral	6.0%	22.9	16.9	17.0%	
Infosys	3,218	41.4	Buy	15.0%	21.5	14.8	22.9%	
Wipro	476	26.2	Sell	-7.5%	19.7	14.0	12.6%	
HCL Tech	467	7.0	Sell	-9.0%	15.2	8.9	21.8%	
MphasiS	421	2.0	Neutral	18.8%	10.9	7.2	-13.0%	
Patni	474	1.4	Buy	11.7%	11.8	6.8	-0.1%	
TechMahindra	691	1.9	Neutral	5.0%	11.2	6.4	5.9%	
Mahindra Satyam	66	1.7	Sell	-1.8%	18.5	10.2	24.0%	

Above data as at 1 April 2011. Note: Year-end June 2011 for HCLT; December 2011 for Patni; October 2011 for MphasiS.

Source: Company data, UBS estimates

Table 3: Quarterly US\$ versus Rs revenue growth rates

		Dec-08	Mar-09	Jun-09	Sep-09	Dec-09	Mar-10	Jun-10	Sep-10	Dec-10	Mar-11E
Infosys	US\$ growth (%)	(3.7)	(4.3)	0.1	2.9	6.8	5.2	4.8	10.2	5.9	4.6
	Rs growth (%)	6.8	(2.6)	(2.9)	2.1	2.8	3.5	4.3	12.1	2.3	5.5
TCS	US\$ growth (%)	(5.8)	(3.4)	3.3	3.8	6.3	3.1	6.4	11.7	7.0	5.8
103	Rs growth (%)	4.7	(1.4)	0.5	3.2	2.9	1.1	6.2	13.0	4.1	6.1
Winna	US\$ growth (%)	(0.9)	(4.9)	(1.3)	3.2	5.8	3.5	3.2	5.7	5.6	4.2
Wipro	Rs growth (%)	6.2	(0.8)	(3.6)	3.6	3.3	1.8	4.6	4.5	3.5	5.3
HCL Tech	US\$ growth (%)	0.5	11.3	7.6	3.8	3.4	5.1	7.6	9.0	7.5	4.9
HCL Tech	Rs growth (%)	4.2	15.9	1.6	4.2	0.0	1.4	11.4	5.4	6.9	4.9
MphasiS	US\$ growth (%)	9.0	4.0	11.0	0.5	9.8	5.4	1.8	7.5	(8.5)	2.8
	Rs growth (%)	9.3	7.2	5.4	2.4	5.2	2.4	4.8	5.2	(8.3)	2.2
Dotni	US\$ growth (%)	0.6	(7.2)	(2.8)	4.0	(1.8)	(1.9)	0.4	2.4	2.9	7.3
Patni	Rs growth (%)	(3.9)	(11.4)	3.5	3.3	1.8	1.3	(2.8)	6.7	2.3	6.5
TechM	US\$ growth (%)	(14.0)	(8.8)	7.7	3.9	7.3	1.9	(2.9)	30.7	(18.1)	3.3
i echivi	Rs growth (%)	(2.8)	(7.1)	5.9	2.6	4.0	(0.3)	(4.2)	35.3	(21.0)	3.8

Note: Year-end June 2011 for HCLT; December 2011 for Patni; October 2011 for MphasiS.

Source: Company data, UBS estimates

Statement of Risk

We believe a sharp decline in IT spending or currency appreciation could result in downward revisions in earnings estimates.

■ Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Required Disclosures

This report has been prepared by UBS Securities India Private Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating	Rating Category	Coverage ¹	IB Services ²
Buy	Buy	52%	41%
Neutral	Hold/Neutral	40%	37%
Sell	Sell	8%	20%
UBS Short-Term Rating	Rating Category	Coverage ³	IB Services ⁴
Buy	Buy	less than 1%	30%
Sell	Sell	less than 1%	17%

^{1:}Percentage of companies under coverage globally within the 12-month rating category.

Source: UBS. Rating allocations are as of 31 March 2011.

UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition
Buy	FSR is > 6% above the MRA.
Neutral	FSR is between -6% and 6% of the MRA.
Sell	FSR is > 6% below the MRA.
UBS Short-Term Rating	Definition
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.

^{2:}Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

^{3:}Percentage of companies under coverage globally within the Short-Term rating category.

^{4:}Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

KEY DEFINITIONS

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months.

Market Return Assumption (MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

Equity Price Targets have an investment horizon of 12 months.

EXCEPTIONS AND SPECIAL CASES

UK and European Investment Fund ratings and definitions are: Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities India Private Ltd: Diviya Nagarajan.

Company Disclosures

Company Name	Reuters	12-mo rating	Short-term rating	Price	Price date
HCL Technologies	HCLT.BO	Sell	N/A	Rs467.05	01 Apr 2011
Infosys Technologies Ltd. 16, 18a	INFY.BO	Buy	Buy	Rs3,218.20	01 Apr 2011
Mahindra Satyam ¹⁶	SATY.BO	Sell	N/A	Rs66.20	01 Apr 2011
MphasiS Limited	MBFL.BO	Neutral	N/A	Rs420.80	01 Apr 2011
Patni Computer Systems ¹⁶	PTNI.BO	Buy	N/A	Rs474.45	01 Apr 2011
Tata Consultancy Services Ltd.	TCS.BO	Neutral	N/A	Rs1,179.65	01 Apr 2011
Tech Mahindra ⁵	TEML.BO	Neutral	N/A	Rs690.75	01 Apr 2011
Wipro Ltd. ^{16, 18b}	WIPR.BO	Sell	N/A	Rs475.85	01 Apr 2011

Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

- 5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
- 16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.
- 18a. The U.S. equity strategist, a member of his team, or one of their household members has a long position in the ADRs of Infosys Technologies Ltd.
- 18b. The U.S. equity strategist, a member of his team, or one of their household members has a position in the ADRs of Wipro Ltd.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Publishing Administration.

Global Disclaimer

This report has been prepared by UBS Securities India Private Ltd, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is referred to as UBS SA.

This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors should not be regarded by recipients as a substitute for the exercise of their own judgement. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysi

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or iliquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein.

Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited and regulated by the Financial Services Authority (FSA). UBS research complies with all the FSA requirements and laws concerning disclosures and these are inclicated on the research where applicable. France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. as regulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzdienstelistungsaufsicht (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. As contributed to this report, the report is also deemed by UBS Limited and distributed by UBS Securities France SA. As contributed by UBS Careful and distributed by UBS Careful and UBS Securities Sepana SV. SA. UBS Securities Sepana SV. SA UBS is regulated by the Comisión Nacional del Mercado de Valores (CNMV). Turkey: Prepared by UBS Menkul Degerler AS on behalf of and distributed by UBS Limited and UBS Italia Sim S.p.A. Is regulated by the Bank of Italy and by the Commissione Nazionale per le Società e la Borsa (CONSOB). Where an analyst of UBS Italia Sim S.p.A. as contributed to this report, the report is also deemed to have been prepared by UBS Italia Sim S.p.A. as contributed by UBS Limited and UBS Italia Sim S.p.A. as contributed by UBS Careful Signary and Agrica (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited, the South Africa (Pty) Limited (Registration No. 1995/011140/07) is a member of the JSE Limited. The report is also deemed to

The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2011. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

